On Saturday, Feb. 27, 2021, Johnson & Johnson's Janssen COVID-19 vaccine received authorization from the Food and Drug Administration for emergency use in adults during the pandemic. The next day, the Centers for Disease Control and Prevention's vaccine advisory committee followed with its endorsement of the vaccine's safety and efficacy.
By March 1, the company had begun shipping 3.9 million doses of its vaccine across the country, with supply expected to scale up in future weeks and months. The shots will be distributed to states, tribes, territories, pharmacies and community health centers, said Jeff Zients, the White House's COVID-19 response coordinator, at a briefing Monday. The shot offers COVID-19 protection with one dose.
According to an article in the New York Times, Johnson & Johnson signed a $1 billion contract to deliver 37 million doses by the end of March and a total of 100 million by the end of June.